| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 06/19/2002 | EP1214304A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| 06/19/2002 | EP1214293A1 Non-peptidic cyclophilin binding compounds and their use |
| 06/19/2002 | EP1214292A1 Tyrosine derivatives |
| 06/19/2002 | EP1214090A2 Novel uses of mammalian ccr6 receptors and related reagents |
| 06/19/2002 | EP1214089A1 Therapeutic uses of m3 polypeptide |
| 06/19/2002 | EP1214087A1 Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| 06/19/2002 | EP1214079A1 Drug for treating fractures |
| 06/19/2002 | EP1213975A2 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds, and therapeutic, cosmetical or food use of said compounds |
| 06/19/2002 | EP0980354B1 Vitamin d3 analogs with bis c-20 side chains |
| 06/19/2002 | EP0753302B1 Osteoporosis preventing or treating agent |
| 06/19/2002 | CN1354750A Amine derivatives compounds |
| 06/19/2002 | CN1354653A Compressed compositions comprising clarified xanthan gum |
| 06/19/2002 | CN1354640A Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 06/19/2002 | CN1353988A Medicine for curing osteopathy |
| 06/19/2002 | CN1353985A Matter or composition for treatment of cancer |
| 06/19/2002 | CN1086295C External used medicinal liquor |
| 06/19/2002 | CN1086293C External used Chinese medicine preparation for traumatic injury |
| 06/19/2002 | CN1086292C Scorption and ant medicinal liquor |
| 06/18/2002 | US6407250 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists |
| 06/18/2002 | US6407067 Salts of thrombin inhibitors |
| 06/18/2002 | CA2356812A1 Tnf-alpha production inhibitor comprising kavalactone as an active ingredient |
| 06/18/2002 | CA2241725C Growth-hormone secretagogues |
| 06/13/2002 | WO2002046749A2 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | WO2002046412A2 Regulation of angiogenesis with zinc finger proteins |
| 06/13/2002 | WO2002046409A2 Proteins and nucleic acids encoding same |
| 06/13/2002 | WO2002046386A2 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase |
| 06/13/2002 | WO2002046384A2 Kinases and phosphatases sequences, and use thereof |
| 06/13/2002 | WO2002046383A2 Protein modification and maintenance molecules |
| 06/13/2002 | WO2002046364A2 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 06/13/2002 | WO2002046226A2 Trefoil factor 2 (tff2) peptides with moiety attached to asn15 |
| 06/13/2002 | WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | WO2002046214A2 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | WO2002046197A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 06/13/2002 | WO2002046182A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | WO2002046178A2 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 06/13/2002 | WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046168A1 Therapeutic benzimidazole compounds |
| 06/13/2002 | WO2002046164A1 Therapeutic compounds |
| 06/13/2002 | WO2002046158A2 Piperidine/piperazine-type inhibitors of p38 kinase |
| 06/13/2002 | WO2002046154A1 Peroxisome proliferator activated receptor d activators |
| 06/13/2002 | WO2002046148A1 Substituted anthranilic acids |
| 06/13/2002 | WO2002046147A2 Perturbed membrane-binding compounds |
| 06/13/2002 | WO2002046138A2 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | WO2002046134A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | WO2002045766A1 Tissue equivalant for transplantation and process for producing the same |
| 06/13/2002 | WO2002045754A2 Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| 06/13/2002 | WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination |
| 06/13/2002 | WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases |
| 06/13/2002 | WO2002045652A2 Tyrosine kinase inhibitors |
| 06/13/2002 | WO2002028842A3 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist |
| 06/13/2002 | WO2002026929A3 Kini-3 motor protein and methods for its use |
| 06/13/2002 | WO2002026706A3 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
| 06/13/2002 | WO2002018353A3 Oxazolidinone chemotherapeutic agents |
| 06/13/2002 | WO2002017857A3 Methods and compositions for inhibiting angiogenesis |
| 06/13/2002 | WO2002008222A3 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS |
| 06/13/2002 | WO2001096330A3 Thrombin receptor antagonists |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001082899A3 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| 06/13/2002 | WO2001077057A3 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 06/13/2002 | WO2001076577A3 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| 06/13/2002 | WO2001064889A3 Tnf-alpha variants for the treatment of tnf-alpha related disorders |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072616 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 06/13/2002 | US20020072609 Process for preparing arylacetylaminothiazoles |
| 06/13/2002 | US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant |
| 06/13/2002 | US20020072533 Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt |
| 06/13/2002 | US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma |
| 06/13/2002 | US20020072526 Orally active salts with tyrosine kinase activity |
| 06/13/2002 | US20020072518 Bicyclic alphavbeta3 antagonists |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072500 3-(carboxy(hydroxy)alkylaminocarbonylmethylaminocarbonyl), 5-(tetrahydropyrimidin-2-yl-amino)phenol for example |
| 06/13/2002 | US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072107 Human osteoclast derived cathepsin |
| 06/13/2002 | US20020072066 Human osteoporosis gene |
| 06/13/2002 | US20020071857 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | DE10059336A1 Herstellung von rekombinantem BMP-2 Production of recombinant BMP-2 |
| 06/13/2002 | CA2437048A1 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 06/13/2002 | CA2436899A1 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | CA2436870A1 Substituted anthranilic acids |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430769A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2429258A1 Piperidine/piperazine-type inhibitors of p38 kinase |
| 06/13/2002 | CA2428097A1 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | CA2427615A1 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase |